Spherix Global Insights

Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic atrophy (GA) feels very similar to the…

Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with additional options to treat lupus…

Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients. While several agents within the class…

Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight, including 40% being clinically obese.   Nearly…

Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia areata (AA).​​At one-year post approval,…

Exton, Pennsylvania, June 28, 2023 (GLOBE NEWSWIRE) -- With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy (GA), patients gained access to the first and only…

Exton, Pennsylvania, June 23, 2023 (GLOBE NEWSWIRE) -- Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars Today and Tomorrow (US) series since Q4…